Faculty of Pharmacy, University of Sydney, Australia.
J Sleep Res. 2011 Dec;20(4):559-68. doi: 10.1111/j.1365-2869.2011.00919.x. Epub 2011 Apr 11.
A prominent media publicity cluster during 2007-2008 in Australia linked the common hypnotic zolpidem to adverse drug reaction reports of parasomnias, amnesia, hallucinations and suicidality. The collection of adverse drug reaction data through spontaneous reporting systems is a mainstay of drug safety monitoring, but a stimulated reporting event such as this often renders such data uninterpretable. As such, we aimed to investigate whether these associations were present before the media cluster and then to quantify the effect of stimulated reporting on those four specific outcomes. Using disproportionality analyses we compared zolpidem to all other drugs in the database, and then separately to each of all hypnotics, then all benzodiazepines, and then temazepam alone, and did so in every year from 2001 to 2008. Year-by-year analyses of Reporting odds ratios for zolpidem exposure and adverse events of interest, adjusted for a number of covariates, revealed an association between zolpidem exposure and parasomnias, amnesia and hallucination both before and after the cluster of media publicity beginning in early 2007. The odds ratios increased significantly after the media publicity for only parasomnias and amnesia. Suicidality was increased in some analyses, but limited data make this outcome difficult to interpret. We conclude that zolpidem adverse drug reaction reports have higher odds for parasomnia, amnesia, hallucination and perhaps suicidality compared to either all other drugs or hypnotics, even before the media publicity cluster. However, the extant literature and the limitations of these spontaneously reported adverse drug reaction data do not allow us to conclude that these events are related causally to zolpidem.
2007-2008 年期间,澳大利亚有一段突出的媒体宣传,将常见的催眠药物唑吡坦与不良药物反应报告中的睡眠障碍、遗忘症、幻觉和自杀意念联系起来。通过自发报告系统收集不良药物反应数据是药物安全监测的主要手段,但像这样的刺激报告事件通常使得这些数据无法解释。因此,我们旨在调查这些关联是否在媒体集群之前存在,然后量化刺激报告对这四个特定结果的影响。我们使用不相称性分析将唑吡坦与数据库中的所有其他药物进行比较,然后分别与所有催眠药物、所有苯二氮䓬类药物以及单独的替马西泮进行比较,并且在 2001 年至 2008 年的每一年都进行了比较。对唑吡坦暴露和不良事件的报告比值比进行逐年分析,并针对多个协变量进行调整,结果表明,在 2007 年初开始的媒体宣传集群之前和之后,唑吡坦暴露与睡眠障碍、遗忘症和幻觉之间存在关联。仅在媒体宣传之后,唑吡坦暴露与睡眠障碍和遗忘症的比值比显著增加。自杀意念在一些分析中增加,但数据有限,使得这一结果难以解释。我们的结论是,与所有其他药物或催眠药物相比,唑吡坦的不良药物反应报告更有可能出现睡眠障碍、遗忘症、幻觉,甚至可能出现自杀意念,即使在媒体宣传集群之前也是如此。然而,现有文献和这些自发报告的不良药物反应数据的局限性不允许我们得出这些事件与唑吡坦有因果关系的结论。